id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-2626	Inno, Alessandro; Bogina, Giuseppe; Settanni, Giulio; Salgarello, Matteo; Foti, Giovanni; Pomari, Carlo; Picece, Vincenzo; Gori, Stefania	First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression	2023	4	.pdf	application/pdf	2598	163	57	Keywords: Elderly, First-line treatment, MET 14-exon skipping mutation, MET inhibitor, Non-small cell lung cancer, Tepotinib Received: July 3, 2023 Accepted: September 19, 2023 Published online: October 6, 2023 Corresponding author: Alessandro Inno Medical Oncology IRCCS Ospedale Sacro Cuore Don Calabria Via don A. Sempreboni 5 37024 Negrar di Valpolicella (VR) - Italy alessandro.inno@sacrocuore.it patients (2,3). Stage was cT1c N0 M1c, IVB according to the American Introduction Mesenchymal epithelial transition gene (MET) exon 14 (METex14) skipping mutations occur in approximately 3-4% of non-small cell lung cancer (NSCLC) (1).	cache/dti-2626.pdf	txt/dti-2626.txt